Business Description
NexImmune Inc
NAICS : 541713
SIC : 2834
ISIN : US65344D2080
Share Class Description:
STU:7370: Ordinary SharesDescription
NexImmune Inc is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. The company has two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History |
|---|
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History |
|---|
GF Value Rank
| Name | Current | Vs Industry | Vs History |
|---|
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NexImmune Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -17.217 | ||
| Beta | 0.5023 | ||
| 3-Year Sharpe Ratio | -0.82 | ||
| 3-Year Sortino Ratio | -0.82 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 4.55 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 4.55 - 4.55 | ||
| Shares Outstanding (Mil) | 1.39 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NexImmune Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NexImmune Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-16 | In 127 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 33 days | ||
| First quarter earnings results for 2026 | 2026-07-22 | In 10 days | ||
| General meeting for 2025 | 2026-07-15 | In 3 days | ||
| Annual report for 2025 | 2026-07-10 | 4.55 (+0.00%) | ||
| Second quarter earnings results for 2024 | 2024-08-07 | 4.55 (+0.00%) | ||
| 0.04:1 Stock Split | 2023-10-19 | 4.55 (-8.54%) |
Show
Entries
NexImmune Inc Frequently Asked Questions
What is NexImmune Inc(STU:7370)'s stock price today?
The current price of STU:7370 is €4.55. The 52 week high of STU:7370 is €4.55 and 52 week low is €4.55.
When is next earnings date of NexImmune Inc(STU:7370)?
The next earnings date of NexImmune Inc(STU:7370) is 2026-07-22 Est..
Does NexImmune Inc(STU:7370) pay dividends? If so, how much?
NexImmune Inc(STU:7370) does not pay dividend.
Press Release
Articles on NexImmune Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers